HK1208164A1 - Compositions comprising short-acting benzodiazepines - Google Patents
Compositions comprising short-acting benzodiazepines Download PDFInfo
- Publication number
- HK1208164A1 HK1208164A1 HK15108782.8A HK15108782A HK1208164A1 HK 1208164 A1 HK1208164 A1 HK 1208164A1 HK 15108782 A HK15108782 A HK 15108782A HK 1208164 A1 HK1208164 A1 HK 1208164A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- composition
- dextran
- lactose
- lyophilized
- benzodiazepine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
- Lyophilisierte oder sprühgetrocknete Zusammensetzung, umfassend wenigstens ein Benzodiazepin gemäß der Formel (I) wobeiW H ist;X CH2 ist; n 1 ist;Y CH2 ist; m 1 ist;Z O ist;R1 CH3, CH2CH3, CH2CH2CH3, CH(CH3)2 oder CH2CH(CH3)2 ist;R2 2-Fluorphenyl, 2-Chlorphenyl oder 2-Pyridyl ist;R3 Cl oder Br ist;R4, R5 und R6 die Gruppe -CR8=U-V= bildet, wobei R8 Wasserstoff, C1-4-Alkyl oder C1-3-Hydroxyalkyl ist, U N oder CR9 ist, wobei R9 H, C1-4-Alkyl, C1-3-Hydroxyalkyl oder C1-4-Alkoxy ist, V N oder CH ist, und p Null ist;oder ein pharmazeutisch akzeptables Salz davon, wobei die Zusammensetzungwenigstens einen pharmazeutisch akzeptablen hygroskopischen Arzneiträger umfasst, wobei der hygroskopische Arzneiträger ein Kohlenhydrat ist, das ausgewählt ist aus der Gruppe bestehend aus Disacchariden und Dextran, und wobei die Zusammensetzung optional wenigstens teilweise amorph ist.
- Zusammensetzung nach Anspruch 1, wobei das Benzodiazepin gemäß Formel (I) Methyl 3-[(4S)-8-brom-1-methyl-6-(pyridin-2-yl)-4H-imidazol[1,2-a][1,4]benzodiazepin-4-yl]propanoat (Remimazolam) ist.
- Zusammensetzung nach Anspruch 2, wobei das pharmazeutisch akzeptable Salz des Benzodiazepins in kationischer Form formuliert ist, und wobei das Gegenion Benzolsulfonat (Besylat) ist.
- Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei das Dextran ein Molekulargewicht von 150 kD besitzt.
- Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei das Disaccharid ausgewählt ist aus der Gruppe bestehend aus Laktose, Maltose, Saccharose, und Trehalose.
- Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei die Zusammensetzung ein Gemisch aus einem ersten hygroskopischen Arzneiträger und einem zweiten hygroskopischen Arzneiträger umfasst.
- Zusammensetzung nach Anspruch 6, wobei die Zusammensetzung ein Gemisch aus Disaccharid und Dextran umfasst, vorzugsweise ein Gemisch aus Laktose und Dextran.
- Zusammensetzung nach Anspruch 7, wobei das Gewichtsverhältnis zwischen Laktose und Dextran zwischen 1:1,0 und 1:10 liegt, vorzugsweise zwischen 1:1,2 und 1:5 und darüber hinaus bevorzugt 1:1,5 oder 1:4.
- Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei das Gewichtsverhältnis zwischen der Gesamtmenge hygroskopischer Arzneiträger und der Gesamtmenge an Benzodiazepinen oder Salzen davon, berechnet für die Base, in der Zusammensetzung zwischen 20:1 und 1:1 liegt, vorzugsweise zwischen 12:1 und 3:1, wobei ein Wert zwischen 9:1 und 3:1 am meisten bevorzugt ist.
- Zusammensetzung nach einem der Ansprüche 1 bis 3, bei der es sich um eine pharmazeutische Formulierung handelt.
- Verwendung eines Gemischs aus wenigstens einem Disaccharid und wenigstens einem Dextran für die Herstellung einer lyophilisierten oder sprühgetrockneten pharmazeutischen Zusammensetzung, umfassend ein Benzodiazepin mit einem Carbonsäureesteranteil gemäß Anspruch 1 oder ein pharmazeutisch akzeptables Salz davon, insbesondere Remimazolam.
- Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die folgenden Schritte umfassend:a) Bereitstellen einer Lösung, umfassend ein Benzodiazepin nach Anspruch 1 oder ein pharmazeutisch akzeptables Salz davon, insbesondere Remimazolam;b) Zugabe wenigstens eines hygroskopischen Arzneiträgers, bei dem es sich um ein Kohlenhydrat handelt, das ausgewählt ist aus der Gruppe bestehend aus Disacchariden und Dextran oder einem Gemisch davon mit wenigstens einem weiteren hygroskopischen Arzneiträger;c) Trocknen der Lösung aus Schritt b) durch Lyophilisation oder Sprühtrocknen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168968 | 2012-05-22 | ||
| EP12168968.1 | 2012-05-22 | ||
| PCT/EP2013/060543 WO2013174883A1 (en) | 2012-05-22 | 2013-05-22 | Compositions comprising short-acting benzodiazepines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1208164A1 true HK1208164A1 (en) | 2016-02-26 |
| HK1208164B HK1208164B (en) | 2018-06-29 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2852389B1 (de) | Zusammensetzungen mit kurzzeitwirkenden benzodiazepinen | |
| JP5380549B2 (ja) | ボリコナゾール含有の薬物製剤及びその調製方法 | |
| Abed et al. | Formulation and optimization of orodispersible tablets of diazepam | |
| TW200944508A (en) | Novel solid forms of bendamustine hydrochloride | |
| ES2573982T3 (es) | Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina | |
| EP2811984A1 (de) | Verfahren zur herstellung stabiler pharmazeutischer zusammensetzungen aus für hydrolyse geeigneten verbindungen | |
| BR112012009660B1 (pt) | lipossoma tendo fase de água interna contendo sal de ciclodextrina de éter sulfobutílico, seu processo de preparação, seu uso e preparação farmacêutica lipossômica | |
| TW201930285A (zh) | 共晶體、其藥物組合物以及涉及其的治療方法 | |
| HK1208164B (en) | Compositions comprising short-acting benzodiazepines | |
| EP1945182B1 (de) | Formulierungen von tipifarnib zur intravenösen verabreichung | |
| CN108289897B (zh) | 一种瑞马唑仑的药物组合物 | |
| JP2019512538A (ja) | オリタバンシン製剤 | |
| CN112175029A (zh) | 抗真菌的大环多烯类新化合物 | |
| US9308174B2 (en) | Lyophilized formulations of bendamustine hydrochloride | |
| OA20108A (en) | Compositions Comprising Short-Acting Benzodiazepines. | |
| Almarsson et al. | Solid-state chemistry of a novel carbapenem with a releasable sidechain | |
| Cutrignelli et al. | Dasatinib/HP-ẞ-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the | |
| CN111100122A (zh) | 左旋四氢帕马丁新化合物 | |
| HK40116191A (en) | Platform drug delivery system utilizing crystal engineering and theanine dissolution | |
| BR112015005489B1 (pt) | Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas | |
| EP2976067A1 (de) | Pharmazeutische zusammensetzung mit einem antibakteriellen fluorchinolonwirkstoff und verfahren zur herstellung davon |